miR‑150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B‑cell lymphoma

Wang,Xinyuan; Kan,Yutian; Chen,Leiyuan; Ge,Peng; Ding,Tingting; Zhai,Qiongli; Yu,Yong; Wang,Xiaofang; Zhao,Zhigang; Yang,Hongliang; Liu,Xianming; Li,Lanfang; Qiu,Lihua; Qian,Zhengzi; Zhang,Huilai; Wang,Yafei; Zhao,Haifeng

doi:10.3892/ol.2020.11452

miR‑150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B‑cell lymphoma

Authors:
- Xinyuan Wang
- Yutian Kan
- Leiyuan Chen
- Peng Ge
- Tingting Ding
- Qiongli Zhai
- Yong Yu
- Xiaofang Wang
- Zhigang Zhao
- Hongliang Yang
- Xianming Liu
- Lanfang Li
- Lihua Qiu
- Zhengzi Qian
- Huilai Zhang
- Yafei Wang
- Haifeng Zhao
View Affiliations

Affiliations: Department of Hematology and Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, P.R. China
Published online on: March 10, 2020 https://doi.org/10.3892/ol.2020.11452
Pages: 3487-3494
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A number of studies suggest an association between miRNAs and diffuse large B‑cell lymphoma (DLBCL). The present study aimed to investigate the prognostic value of microRNA (miR‑150) in primary gastrointestinal (PGI)‑DLBCL, by assessing the association between miR‑150 expression and clinicopathological characteristics in patients with PGI‑DLBCL. A total of 84 patients diagnosed with PGI‑DLBCL were recruited and both tumor and adjacent non‑tumor tissue samples were collected. miR‑150 expression was assessed via reverse transcription‑quantitative (RT‑q)PCR analysis. The results demonstrated that miR‑150 expression was significantly lower in PGI‑DLBCL tissues compared with adjacent non‑tumor tissues. Furthermore, receiver operating characteristic (ROC) curve analysis indicated that the optimal cut‑off value of miR‑150 for predicting survival was 8.965 with high sensitivity (79.8%) and specificity (77.1%). Patients were divided into two groups according to this cut‑off value, as follows: High (n=18) and low expression (n=66) groups. Low miR‑150 expression was significantly associated with clinical stage, International Prognostic Index (IPI), Eastern Cooperative Oncology Group status and use of rituximab. RT‑qPCR analysis demonstrated that miR‑150 expression was significantly lower in patients with high IPI scores compared with patients with low IPI scores. Downregulated miR‑150 expression was significantly associated with shorter overall survival (OS) time and progression‑free survival (PFS) time in patients with PGI‑DLBCL. Furthermore, miR‑150 level and IPI score were identified as two risk factors for OS and PFS. The diagnostic value of miR‑150 was evaluated via ROC curve analysis, with an area under the curve value of 0.882. Taken together, the results of the present study suggest that miR‑150 is a potential diagnostic marker of PGI‑DLBCL, and may also serve as a useful prognostic factor for survival outcomes in patients with PGI‑DLBCL.

View Figures

View References

1	Peng JC, Zhong L and Ran ZH: Primary lymphomas in the gastrointestinal tract. J Dig Dis. 16:169–176. 2015. View Article : Google Scholar : PubMed/NCBI
2	Wang T, Gui W and Shen Q: Primary gastrointestinal non-Hodgkin's lymphoma: Clinicopathological and prognostic analysis. Med Oncol. 27:661–666. 2010. View Article : Google Scholar : PubMed/NCBI
3	Cogliatti SB, Schmid U, Schumacher U, Eckert F, Hansmann ML, Hedderich J, Takahashi H and Lennert K: Primary B-cell gastric lymphoma: A clinicopathological study of 145 patients. Gastroenterology. 101:1159–1170. 1991. View Article : Google Scholar : PubMed/NCBI
4	Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, et al: Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German multicenter study GIT NHL 01/92. J Clin Oncol. 19:3861–3873. 2001. View Article : Google Scholar : PubMed/NCBI
5	Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C, Xiros N and Economopoulos T: Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A hellenic cooperative oncology group study (HeCOG). Leuk Lymphoma. 47:2140–2146. 2006. View Article : Google Scholar : PubMed/NCBI
6	Suresh B, Asati V, Lakshmaiah KC, Babu G, Lokanatha D, Jacob LA, Lokesh KN, Rudresh AH, Rajeev LK, Smitha S, et al: Primary gastrointestinal diffuse large B-cell lymphoma: A prospective study from South India. South Asian J Cancer. 8:57–59. 2019. View Article : Google Scholar : PubMed/NCBI
7	Chen K and Rajewsky N: The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 8:93–103. 2007. View Article : Google Scholar : PubMed/NCBI
8	Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, et al: MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar : PubMed/NCBI
9	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
10	Zhu FQ, Zeng L, Tang N, Tang YP, Zhou BP, Li FF, Wu WG, Zeng XB and Peng SS: MicroRNA-155 downregulation promotes cell cycle arrest and apoptosis in diffuse large B-cell lymphoma. Oncol Res. 24:415–427. 2016. View Article : Google Scholar : PubMed/NCBI
11	Zhuang H, Shen J, Zheng Z, Luo X, Gao R and Zhuang X: MicroRNA-146a rs2910164 polymorphism and the risk of diffuse large B cell lymphoma in the Chinese Han population. Med Oncol. 31:3062014. View Article : Google Scholar : PubMed/NCBI
12	Berglund M, Hedström G, Amini RM, Enblad G and Thunberg U: High expression of microRNA-200c predicts poor clinical outcome in diffuse large B-cell lymphoma. Oncol Rep. 29:720–724. 2013. View Article : Google Scholar : PubMed/NCBI
13	Ivey KN and Srivastava D: microRNAs as developmental regulators. Cold Spring Harb Perspect Biol. 7:a0081442015. View Article : Google Scholar : PubMed/NCBI
14	Larrabeiti-Etxebarria A, Lopez-Santillan M, Santos-Zorrozua B, Lopez-Lopez E and Garcia-Orad A: Systematic review of the potential of MicroRNAs in diffuse large B cell lymphoma. Cancers (Basel). 11(pii): E1442019. View Article : Google Scholar : PubMed/NCBI
15	Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 11:597–610. 2010. View Article : Google Scholar : PubMed/NCBI
16	Koscianska E and Krzyzosiak WJ: Current understanding of the role of microRNAs in spinocerebellar ataxias. Cerebellum Ataxias. 1:72014. View Article : Google Scholar : PubMed/NCBI
17	Bi N, Cao J, Song Y, Shen J, Liu W, Fan J, He J, Shi Y, Zhang X, Lu N, et al: A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy. PLoS One. 9:e913882014. View Article : Google Scholar : PubMed/NCBI
18	Tang W, Xu P, Wang H, Niu Z, Zhu D, Lin Q, Tang L and Ren L: MicroRNA-150 suppresses triple-negative breast cancer metastasis through targeting HMGA2. Onco Targets Ther. 11:2319–2332. 2018. View Article : Google Scholar : PubMed/NCBI
19	Yokobori T, Suzuki S, Tanaka N, Inose T, Sohda M, Sano A, Sakai M, Nakajima M, Miyazaki T, Kato H and Kuwano H: miR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 104:48–54. 2013. View Article : Google Scholar : PubMed/NCBI
20	Ma Y, Zhang P, Wang F, Zhang H, Yang J, Peng J, Liu W and Qin H: miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 61:1447–1453. 2012. View Article : Google Scholar : PubMed/NCBI
21	Lee KH, Lee JK, Choi DW, Do IG, Sohn I, Jang KT, Jung SH, Heo JS, Choi SH and Lee KT: Postoperative prognosis prediction of pancreatic cancer with seven microRNAs. Pancreas. 44:764–768. 2015. View Article : Google Scholar : PubMed/NCBI
22	Huang S, Chen Y, Wu W, Ouyang N, Chen J, Li H, Liu X, Su F, Lin L and Yao Y: miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS One. 8:e807072013. View Article : Google Scholar : PubMed/NCBI
23	Yin QW, Sun XF, Yang GT, Li XB, Wu MS and Zhao J: Increased expression of microRNA-150 is associated with poor prognosis in non-small cell lung cancer. Int J Clin Exp Pathol. 8:842–846. 2015.PubMed/NCBI
24	Dezhong L, Xiaoyi Z, Xianlian L, Hongyan Z, Guohua Z, Bo S, Shenglei Z and Lian Z: miR-150 is a factor of survival in prostate cancer patients. J BUON. 20:173–179. 2015.PubMed/NCBI
25	Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE and Nikiforova MN: MicroRNA profile of poorly differentiated thyroid carcinomas: New diagnostic and prognostic insights. J Mol Endocrinol. 52:181–189. 2014. View Article : Google Scholar : PubMed/NCBI
26	Wang W, Wang X, Zhang Y, Wang D, Gao H, Wang L and Gao S: Prognostic role of microRNA-150 in various carcinomas: A meta-analysis. Onco Targets Ther. 9:1371–1379. 2016. View Article : Google Scholar : PubMed/NCBI
27	Monticelli S, Ansel KM, Xiao C, Socci ND, Krichevsky AM, Thai TH, Rajewsky N, Marks DS, Sander C, Rajewsky K, et al: MicroRNA profiling of the murine hematopoietic system. Genome Biol. 6:R712005. View Article : Google Scholar : PubMed/NCBI
28	Szurián K, Csala I, Piurkó V, Deák L, Matolcsy A and Reiniger L: Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma-proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression. Leuk Res. 58:39–42. 2017. View Article : Google Scholar : PubMed/NCBI
29	Wang M, Yang W, Li M and Li Y: Low expression of miR-150 in pediatric intestinal Burkitt lymphoma. Exp Mol Pathol. 96:261–266. 2014. View Article : Google Scholar : PubMed/NCBI
30	Gebauer N, Kuba J, Senft A, Schillert A, Bernard V and Thorns C: MicroRNA-150 Is up-regulated in extranodal marginal zone lymphoma of MALT type. Cancer Genomics Proteomics. 11:51–56. 2014.PubMed/NCBI
31	Tomonaga M: Outline and direction of revised WHO classification of tumors of haematopoietic and lymphoid tissues. Rinsho Ketsueki. 50:1401–1406. 2009.(In Japanese). PubMed/NCBI
32	Huang J, Jiang W, Xu R, Huang H, Lv Y, Xia Z, Sun X, Guan Z, Lin T and Li Z: Primary gastric non-Hodgkin's lymphoma in Chinese patients: Clinical characteristics and prognostic factors. BMC Cancer. 10:3582010. View Article : Google Scholar : PubMed/NCBI
33	Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, et al: NCCN guidelines insights: Non-Hodgkin's lymphomas, version 3.2016. J Natl Compr Canc Netw. 14:1067–1079. 2016. View Article : Google Scholar : PubMed/NCBI
34	Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al: Revised response criteria for malignant lymphoma. J Clin Oncol. 25:579–586. 2007. View Article : Google Scholar : PubMed/NCBI
35	Ferreri AJ and Montalban C: Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol. 63:65–71. 2007. View Article : Google Scholar : PubMed/NCBI
36	Dawson IM, Cornes JS and Morson BC: Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg. 49:80–89. 1961. View Article : Google Scholar : PubMed/NCBI
37	Nakamura S and Iida M: Molecular genetics in primary gastrointestinal lymphomas. Fukuoka Igaku Zasshi. 99:123–130. 2008.(In Japanese). PubMed/NCBI
38	Nakamura S, Matsumoto T, Nakamura S, Jo Y, Fujisawa K, Suekane H, Yao T, Tsuneyoshi M and Iida M: Chromosomal translocation t(11;18)(q21;q21) in gastrointestinal mucosa associated lymphoid tissue lymphoma. J Clin Pathol. 56:36–42. 2003. View Article : Google Scholar : PubMed/NCBI
39	Lan H, Lu H, Wang X and Jin H: MicroRNAs as potential biomarkers in cancer: Opportunities and challenges. Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI
40	Watanabe A, Tagawa H, Yamashita J, Teshima K, Nara M, Iwamoto K, Kume M, Kameoka Y, Takahashi N, Nakagawa T, et al: The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia. 25:1324–1334. 2011. View Article : Google Scholar : PubMed/NCBI
41	Zhang L, Lin J, Ye Y, Oba T, Gentile E, Lian J, Wang J, Zhao Y, Gu J, Wistuba II, et al: Serum MicroRNA-150 predicts prognosis for early-stage non-small cell lung cancer and promotes tumor cell proliferation by targeting tumor suppressor gene SRCIN1. Clin Pharmacol Ther. 103:1061–1073. 2018. View Article : Google Scholar : PubMed/NCBI
42	He Y, Jiang X and Chen J: The role of miR-150 in normal and malignant hematopoiesis. Oncogene. 33:3887–3893. 2014. View Article : Google Scholar : PubMed/NCBI
43	Fayyad-Kazan H, Bitar N, Najar M, Lewalle P, Fayyad-Kazan M, Badran R, Hamade E, Daher A, Hussein N, ElDirani R, et al: Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med. 11:312013. View Article : Google Scholar : PubMed/NCBI
44	Katada T, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, Ogawa R, Harata K and Fujii Y: microRNA expression profile in undifferentiated gastric cancer. Int J Oncol. 34:537–542. 2009.PubMed/NCBI
45	Song JL, Wei XL, Zhang YK, Hao XX, Huang WM, Wei Q, Wei YQ and Feng R: The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 39:739–744. 2018.(In Chinese). PubMed/NCBI
46	van Imhoff GW, Boerma EJ, van der Holt B, Schuuring E, Verdonck LF, Kluin-Nelemans HC and Kluin PM: Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol. 24:4135–4142. 2006. View Article : Google Scholar : PubMed/NCBI
47	Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI